在本研究中，研究人員計劃對肺癌標本中的「可操作」變異進行全面的分子圖譜分析，以確定本地人群中每種基因亞型的患病率。
適應症：Lung Cancer、Non-Small Cell Lung Cancer
收案條件
納入條件
- The availability of sufficient archival tumor tissue specimen (15 slides of 4 microns per section)
- Age ≥ 21 years
- WHO performance status ≤ 2
- Life expectancy of ≥ 12 weeks
- Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
- Adequate bone marrow function as shown by: ANC ≥ 1.0 x 10\^9/L, Platelets ≥ 75 x 10\^9/L, Hb ≥ 7.5 g/dL
- Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤3.0 x ULN if liver metastases are present)
- Willing to provide signed informed consent
- Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment
排除條件
- \- No more than 3 lines of cytotoxic chemotherapy at the time of enrolment
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。